Literature DB >> 25600113

A potential life-threatening complication after implantation of a bioresorbable scaffold for coronary stenting within a mechanically stressed region.

Karin Schinke1, Nicolas Langwieser, Karl-Ludwig Laugwitz, Tareq Ibrahim.   

Abstract

Mesh：

Year:  2015        PMID： 25600113     DOI： 10.1007/s00392-014-0808-x

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN： 1861-0684            Impact factor:   5.460


× No keyword cloud information.
  3 in total

1.  Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.

Authors:  Davide Capodanno; Tommaso Gori; Holger Nef; Azeem Latib; Julinda Mehilli; Maciej Lesiak; Giuseppe Caramanno; Christoph Naber; Carlo Di Mario; Antonio Colombo; Piera Capranzano; Jens Wiebe; Aleksander Araszkiewicz; Salvatore Geraci; Stelios Pyxaras; Alessio Mattesini; Toru Naganuma; Thomas Münzel; Corrado Tamburino
Journal:  EuroIntervention       Date:  2015-02       Impact factor: 6.534

2.  Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold.

Authors:  Jens Wiebe; Helge Möllmann; Astrid Most; Oliver Dörr; Kay Weipert; Johannes Rixe; Christoph Liebetrau; Albrecht Elsässer; Stephan Achenbach; Christian Hamm; Holger Nef
Journal:  Clin Res Cardiol       Date:  2013-10-18       Impact factor: 5.460

3.  Feasibility of second-generation bioresorbable vascular scaffold implantation in complex anatomical and clinical scenarios.

Authors:  Milosz Jaguszewski; Jelena-Rima Ghadri; Manuel Zipponi; Dana Roxana Bataiosu; Johanna Diekmann; Verena Geyer; Catharina Anna Neumann; Mia Aurelia Huber; Christian Hagl; Paul Erne; Thomas F Lüscher; Christian Templin
Journal:  Clin Res Cardiol       Date:  2014-08-31       Impact factor: 5.460
  3 in total
  1 in total

1.  Use of a bioresorbable novolimus eluting vascular scaffold fails a hybrid PCI strategy with drug eluting stent.

Authors:  Vera S Schneider; Carsten Skurk; Matthias Riedel; Youssef S Abdelwahed; Ulf Landmesser; David M Leistner
Journal:  Clin Res Cardiol       Date:  2017-04-03       Impact factor: 5.460
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.